Ben Solomon is a board-certified pediatric geneticist who focuses on the use of genetics and genomics to identify, understand and care for patients with both rare and common genetic conditions as well as broad applications of genomic medicine. In addition to his laboratory, clinical, and research leadership and advocacy, Dr. Solomon has authored over 100 peer-reviewed articles, book chapters, and textbooks, and is an active lecturer and educator. Read his full bio.

Interview with Ben Solomon from GeneDx

Q: What need is GeneDx addressing?

A: GeneDx was started in 2000 by two NIH scientists with the mission of making genetic testing accessible for patients with rare diseases. We continue to focus on this mission almost 20 years later, but also continue to grow and evolve with changes in technologies, medical knowledge, clinical practices, and research approaches. We now offer genetic testing for just about every indication related to clinical germline/constitutional indications, from single variant testing to whole genome sequencing, and everything in between.

Q: What are the products and/or services GeneDx offers/develops to address this need? What makes GeneDx unique?

A: As mentioned, we have a very comprehensive genetic testing menu both in terms of assays and technologies but also across clinical (as well as research) indications. We pride ourselves on our deep clinical and molecular expertise in everything we do. We have over 150 MDs or PhDs and over 120 genetic counselors, and our team is incredibly passionate about providing the most accurate and best possible testing for all the clinicians, researchers, patients, and families we have the honor to serve. We really care about what genetic changes mean for patients and the providers they see, and make sure we go the extra mile in explaining the evidence and data behind the result, as we know the field of genetics is complex and ever-changing. Along these lines, we believe in marrying the latest cutting-edge methodological approaches – including artificial intelligence and advanced bioinformatic algorithms – with careful human oversight, as well feel that an optimal approach requires these checks and balances and a lot of TLC!

Q: What is your role at GeneDx and what excites you about your work?

A: I’m the head of GeneDx, so I work with every and all aspect of our company. I really love being able to find answers and results that are especially tricky and difficult, and which may be overlooked by other methods. We are constantly iteratively improving our methods, adding new tests and options, and otherwise refining what we do, and it’s great to be part of a field where constant change is a requirement. We think hard about known disease loci as well as novel or candidate disease genes. It’s great to be part of a field where we can identify “knowns” as well as contribute new knowledge to the field.

I’m also a physician clinical geneticist (I still see patients as a small percent of my time), and my heart really goes back to interactions with patients and families. I see very directly how much that matters, including when no testing is done or a test doesn’t provide answers. In other words, no matter how technologically-advanced we get, there’s tremendous power in the human touch. I like to think of GeneDx as helping support these interactions on a large-scale basis and in some of the most clinically challenging and frankly difficult situations in medicine.

Q: When thinking about GeneDx and the domain GeneDx is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?

A: There are constant breakthroughs in this field, including on the “wet lab” and “dry lab” side. I’m particularly excited about new bioinformatic and related methods that help us detect and understand genetic changes that were previously not able to be interrogated or interpreted. We constantly have situations where we’re able to find answers for patients who were previously tested over months and years through a more piece-meal approach using smaller or less advanced assays.

Q: What are the short-term challenges that GeneDx and its peers are facing?

A: It’s very important for all of us in the industry to make sure that insurance companies and related groups understand the clinical impact, guidelines, and financial effects of genetic testing, and we need to keep having those conversations. It’s also critical to make sure there aren’t logistic barriers erected against clinically-indicated testing. I worry that clinicians are so buried in paperwork that they are taken away from their primary goal and passion, which is taking the best possible care of patients. In addition to making life miserable for clinicians, barriers to clinically-indicated and evidence-based testing can have serious effects on the health of patients.

Q: Is there anything else you would like to share with the PMWC audience?

A: It’s a wonderful time to be in this ever-changing field.

Interview with Daniel Chen from IGM Biosciences

Q: Checkpoint inhibitors, particularly with PD-L1/PD-1 targeting agents, have benefited a broad range of patients with cancer. How will we improve on this?

A: It’s true that PD-L1/PD-1 inhibitors have led to durable responses in a subset of patients, and survival benefit in many of the patients treated- either as monotherapy or combination.

Read More

Call from PMWC 2019 Silicon Valley Program Committee – We Must Accelerate and Deliver on the Promise of Precision Medicine

Precision medicine advancements are real as demonstrated by the high volume of molecular, “precise” drugs on the market, which are based on extensive molecular and translational understanding of the specific drug targets.

Read More

#AI Play in Patient Diagnosis? How Can We Prepare the Next Generation to Make Sense of Enormous Amounts of Health-related Data?

What role should artificial intelligence play in patient diagnosis? How can we best prepare the next generation to make sense of enormous amounts of health-related data? These were just a few of the questions explored at the 15th Precision Medicine World Conference held at Duke University September 24-25, 2018.

Read More

Interview with Daniella Beller, Manager, Maccabi Research Institute Biobank

Q: What makes the Maccabi Research Institute biobank unique?

A: To explain the uniqueness of the Maccabi Biobank (named “Tipa” in Hebrew which means “drop” or “just a little”), first you must know a little about Maccabi.

Read More

Why We Need Public-Private Partnerships (PPP) To Foster Drug Discovery

Investments in pharma R&D has substantially increased over the last decades. Yet there appears to be no clear correlation to the number of newly approved drugs. This fact is accompanied by ever-increasing healthcare costs, fueled by an aging population and the parallel rise in the chronic disease burden.

Read More

Precision Medicine: A Decade of Improving the Standard of Care

In January, PMWC will host its 2019 Silicon Valley event, the largest Precision Medicine conference in the world with over 2,500 attendees gathering at the Santa Clara Convention Center. We are humbled and honored to have reached this stage of growth and are looking forward to continuing our work with key stakeholders and decision makers across the industry to ever strengthen this forum for exchange of critical and timely topics, to move the field of precision medicine forward and to improve the Standard of Care.

Read More

Interview with David Hong from Karius

Q: What need is Karius addressing?

A: Physicians often have difficulty pinpointing the exact pathogen that is causing disease. Conventional diagnostics like blood cultures or PCR can have poor sensitivity due to pretreatment with antibiotics, the breadth of potential pathogens present, and the requirement for invasive procedures to access deep-seated infections.

Read More

Interview with Charles Jaffe, MD, PhD from HL7

Q: What need is HL7 addressing?

A: For more than three decades, HL7 has provided the platform to enable global health data interoperability. This is more important than ever, as the cost of healthcare has increased exponentially, and the complexity of clinical evidence has grown to an almost unmanageable state.

Read More

Interview with Eden Haverfield from Invitae

Q: What need is Invitae addressing?

A: Our mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae is uniquely positioned to answer some of life’s most serious and complex questions with the highest quality genetics and at an affordable price.

Read More

Call by Ralph Snyderman (Duke U.) for Big Changes to Get to the Next Level of Precision Medicine

Beyond next-generation gene sequencing and developing diagnostic tools and targeted therapies, theoverall approach to clinical care has to be re-envisioned to fulfill the promise of precision medicine. Care must move from sporadic treatment of episodic disease (a reactive mode) to predicting disease and then acting to prevent and mitigate it (a proactive mode).

Read More

Interview with William Hearl From Immunomic Therapeutics, Inc.

Q: What need is Immunomic Therapeutics, Inc. addressing?

A: Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory.

Read More

Interview with Ralph Snyderman from Duke University

Q: What are some of the critical contributions that academic institutions and medical centers are making to implement and accelerate precision medicine?

A: Over the past decade, the field of precision medicine has created technologies enabling far more personalized and effective health care delivery. Many of the most dramatic advances have come in the field of oncology but targeting care to the needs of the individual is rapidly achieving broader applications.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 16th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 20-23, 2019. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!
pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!